Targeted disruption of TGF-β/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma

American Journal of Pathology

Volumn 165, Issue 1, 2004, Pages 203-217

  Lakos, Gabriella ^a   Takagawa, Shinsuke ^a   Chen, Shu Jen ^a   Ferreira, Ahalia M ^d   Han, Gangwen ^b   Masuda, Koichi ^c   Wang, Xiao Jing ^b   DiPietro, Luisa A ^d   Varga, John ^a,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; BLEOMYCIN; COLLAGEN; HYDROXYPROLINE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FLOW CYTOMETRY; GENE DISRUPTION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; WESTERN BLOTTING;

EID: 3042550759     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63289-0     Document Type: Article

References (64)

1. Kissin EY, Korn JH: Fibrosis in scleroderma. Rheum Dis Clin North Am 2003, 29:351-369
2. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD: Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995, 270:3423-3428
3. Roberts AB: Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998, 24:111-119
4. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor β in human disease. N Engl J Med 2000, 342:1350-1358
5. Kretzschmar M, Massague J: SMADs: mediators and regulators of TGF-β signaling. Curr Opin Genet Dev 1998, 8:103-111
6. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX: Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc Natl Acad Sci USA 1998, 95:9378-9383
7. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF: Targeted disruption of Smad3 reveals an essential role in TGF β-mediated signal transduction. Mol Cell Biol 1999, 19:2495-2504
8. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C: Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 1999, 18:1280-1291
9. Zhao J, Shi W, Wang YL, Chen H, Bringas Jr P, Datto MB, Frederick JP, Wang XF, Warburton D: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002, 282:L585-L593
10. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB: Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999, 1:260-266
11. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP, Roberts AB: Functional characterization of transforming growth factor β signaling in Smad2-and Smad3-deficient fibroblasts. J Biol Chem 2001, 276:19945-19953
12. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003, 425:577-584
13. Mountz JD, Downs Minor MB, Turner R, Thomas MB, Richards F, Pisko E: Bleomycin-induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983, 108:679-686
14. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999, 112:456-462
15. Yamamoto T, Takagawa S, Katayama I, Nishioka K: Anti-sclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999, 92:6-13
16. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J: Sustained activation of fibroblast transforming growth factor-beta/ Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003, 121:41-50
17. Dunphy MJ, Bhide MV, Smith DJ: Determination of hydroxyproline in tissue collagen hydrolysate by derivatization and isocratic reversed-phase high-performance liquid chromatography. J Chromatogr 1987, 420:394-397
18. Varga J, Rosenbloom J, Jimenez SA: Transforming growth factor β causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987, 247:597-604
19. Mori Y, Chen SJ, Varga J: Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003, 48:1964-1978
20. Constantine VS, Mowry RW: Selective staining of human dermal collagen. II: the use of picrosirius red F3BA with polarization microscopy J Invest Dermatol 1968, 50:419-423
21. McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, Bona C: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R α and transforming growth factor-β genes. J Invest Dermatol 2001, 116:136-143
22. Nagata K: Expression and function of heat shock protein 47: a collagen-specific molecular chaperone in the endoplasmic reticulum. Matrix Biol 1998, 16:379-386
23. Jelaska A, Korn JH: Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000, 43:2230-2239
24. Yamamoto T, Nishioka K: Animal model of sclerotic skin. V: increased expression of α-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002, 102:77-83
25. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A: CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001, 276:10594-10601
26. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL: Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol Cell 2000, 6:1365-1375
27. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J: Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. J Invest Dermatol 1999, 112:49-57
28. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB: Autoinduction of transforming growth factor β 1 is mediated by the AP-1 complex. Mol Cell Biol 1990, 10:1492-1497
29. de Sousa Lopes SM, Carvalho RL, van den Driesche S, Goumans MJ, ten Dijke P, Mummery CL: Distribution of phosphorylated Smad2 identifies target tissues of TGF β ligands in mouse development. Gene Expr Patterns 2003, 3:355-360
30. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ: Identification of novel inhibitors of the transforming growth factor β (TGF-β1) type 1 receptor (ALK5). J Med Chem 2002, 45:999-1001
31. Trojanowska M: Molecular aspects of scleroderma. Front Biosci 20021, 7:d608-d618
32. Varga J, Mori Y, Takagawa S: Molecular and cellular basis of fibrosis. Semin Clin Immunol 2000, 2:15-29
33. Zhang Y, McCormick LL, Gilliam AC: Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2003, 12:713-719
34. McCormick LL, Zhang Y, Tootell E, Gilliam AC: Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999, 163:5693-5699
35. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA: Global expression profiling of fibroblast responses to transforming growth factor-β1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 2003, 162:533-546
36. Simms RW, Korn JH: Cytokine-directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol 2002, 14:717-722
37. Vindevoghel L, Kon A, Lechleider RJ, Uitto J, Roberts AB, Mauviel A: Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by TGF-β. J Biol Chem 1998, 273:13053-13057
38. Poncelet AC, Schnaper HW: Sp1 and Smad proteins cooperate to mediate TGF-β 1-induced α 2(I) collagen expression in human glomerular mesangial cells. J Biol Chem 2001, 276:6983-6992
39. Hu B, Wu Z, Phan SH: Smad3 mediates TGF-β-induced α-smooth muscle actin expression. Am J Respir Cell Mol Biol 2003, 397-404
40. Evans RA, Tian YC, Steadman R, Phillips AO: TGF-β1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res 2003, 282:90-100
41. Verrecchia F, Chu ML, Mauviel A: Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001, 276:17058-17062
42. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998, 17:3091-3100
43. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, ten Dijke P, White B, Wigley FM, Goldschmidt-Clermont PJ: Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002, 99:3908-3913
44. Varga J: Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 2002, 46:1703-1713
45. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB: Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987, 84:5788-5792
46. Flanders KC, Major CD, Arabshahi A, Aburime EE, Okada MH, Fujii M, Blalock TD, Schultz GS, Sowers A, Anzano MA, Mitchell JB, Russo A, Roberts AB: Interference with TGF-β/Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. Am J Pathol 2003, 163:2247-2257
47. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S: Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003, 305:1002-1007
48. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A: Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulo-interstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494
49. Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng C, Russo A, Mitchell JB, Roberts AB: Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002, 160:1057-1068
50. Istok R, Bely M, Stancikova M, Rovensky J: Evidence for increased pyridinoline concentration in fibrotic tissues in diffuse systemic sclerosis. Clin Exp Dermatol 2001, 26:545-547
51. Brinckmann J, Notbohm H, Tronnier M, Acil Y, Fietzek PP, Schmeller W, Muller PK, Batge B: Overhydroxylation of lysyl residues is the initial step for altered collagen cross-links and fibril architecture in fibrotic skin. J Invest Dermatol 1999, 113:617-621
52. Gabbiani G: The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003, 200:500-503
53. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA: The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001, 34:89-100
54. Tomasek JJ, Flanders KC, Haaksmao CJ: Smad3 signaling is not required for TGF-β1-promoted myofibroblast differentiation. Wound Rep Regen 2002, 10:A56
55. Qiu P, Feng XH, Li L: Interaction of Smad3 and SRF-associated complex mediates TGF-β1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 2003, 35:1407-1420
56. Uchida K, Suzuki H, Ohashi T, Nitta K, Yumura W, Nihei H: Involvement of MAP kinase cascades in Smad7 transcriptional regulation. Biochem Biophys Res Commun 2001, 289:376-381
57. Xavier S, Pike E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni A, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, Russo A: Amelioration of radiation-induced fibrosis: Inhibtion of transforming growth factor-b signaling by halofuginone. J Biol Chem 2004, 279:15167-15176
58. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K: Alternatively spliced variant of Smad2 lacking exon 3: comparison with wild-type Smad2 and Smad3. J Biol Chem 1999, 274:703-709
59. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271:17779-17784
60. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, Scholmerich J, Michel BA, Gay RE, Matucci-Cerinic M, Gay S, Muller-Ladner U: Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001, 44:2665-2678
61. Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP: Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003, 48:1979-1991
62. Yamamoto T, Nishioka K: Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003, 121:510-516
63. Low QE, Drugea IA, Duffner LA, Quinn DG, Cook DN, Rollins BJ, Kovacs EJ, DiPietro LA: Wound healing in MIP-1 αa(-/-) and MCP-1(-/-) mice. Am J Pathol 2001, 159:457-463
64. Munz B, Smola H, Engelhardt F, Bleuel K, Brauchle M, Lein I, Evans LW, Huylebroeck D, Balling R, Werner S: Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis, and wound repair. EMBO J 1999, 18:5205-5215